Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid

Br J Obstet Gynaecol. 1987 Jun;94(6):554-8. doi: 10.1111/j.1471-0528.1987.tb03150.x.


Thirty-five patients with menorrhagia were treated in a double-blind crossover study with naproxen sodium and mefenamic acid after measurement of their blood loss during control menstrual cycles. Treatment with these compounds reduced the excessive bleeding by an average of 46 and 47% respectively. Drugs in the prostaglandin synthetase inhibitor group are considered to have an important place in the treatment of menorrhagia.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Mefenamic Acid / adverse effects
  • Mefenamic Acid / therapeutic use*
  • Menorrhagia / drug therapy*
  • Naproxen / adverse effects
  • Naproxen / therapeutic use*
  • Random Allocation


  • Mefenamic Acid
  • Naproxen